Peptide compounds and their therapeutic uses

Abstract

To provide novel compositions that may serve to attenuate cellular and immune stress-response in normal tissue, in a manner that is specific, safe and effective, thereby reducing the severity of stress-associated degenerative diseases and stress-induced inflammatory diseases.SOLUTION: The present invention provides an isolated peptide that is 6 amino acids long, comprises a specific amino acid sequence, and is capable of reducing the amount of dexamethasone-induced spleen and / or thymus weight loss in a mouse, and a pharmaceutical composition that comprises the peptide as an active agent and further comprises a physiologically acceptable carrier.SELECTED DRAWING: None

Description

[Technical field]

[0001] Related Applications This application claims priority to Israel Patent Application No. 260555, filed July 11, 2018, the entire contents of which are incorporated herein by reference.

[0002] Sequence Listing The 8,069,120 byte ASCII file “77809 Sequence Listing.txt”, created on July 7, 2019, which was submitted concurrently with the filing of this application, is hereby incorporated by reference into this specification.

[0003] The present invention, in some embodiments, relates to compositions and methods of using same for treating inflammatory and autoimmune diseases. [Background technology]

[0004] There is an unmet need for novel compositions that can specifically, safely and effectively attenuate cellular and immune stress responses in normal tissues and reduce the severity of stress-related degenerative and stress-induced inflammatory diseases.

[0005] The peptide LPPLPYP (SEQ ID NO:2, also known as Stressin-1 and IPL344) is a short 7 amino acid peptide that protects various cell types from proapoptotic pressures and activates the Akt signaling system. The structure of IPL344 resembles the binding sites of adaptor proteins. Its mechanism of action appears to involve mimicking such proteins and activating cytoprotective processes via Akt, possibly by other pathways.

[0006] WO 2006 / 021954 and WO 2012 / 160563 disclose the use of the LPPLPYP (SEQ ID NO: 2) peptide to treat inflammatory and autoimmune diseases, such as ALS. Summary of the Invention

[0007] According to one embodiment of the invention, there is provided an isolated peptide having a length of 10 amino acids or less, comprising: Formula: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 Contains the amino acid sequence represented by SEQ ID NO: 17, (i)X 1 is proline, or an analog or derivative thereof; (ii) X 2 is proline or an analog thereof, (iii)X 3 is selected from the group consisting of alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof; (iv) X 4 is selected from the group consisting of alanine, valine, serine, and derivatives or analogs thereof; (v) X 5 is any amino acid, (vi) X 6 is proline, or an analog or derivative thereof, and (vii) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0008] According to one embodiment of the invention there is provided an isolated peptide having a length of six amino acids or less, comprising: Formula: X 1 -X 2 -X 3 -X 4 -X 5 Contains the amino acid sequence represented by SEQ ID NO:1, (i)X 1 is proline, or an analog or derivative thereof; (ii) X 2 is proline, or an analog or derivative thereof; (iii) X 3 is selected from the group consisting of alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof; (iv) X 4 is selected from the group consisting of alanine, valine, serine, proline, and derivatives or analogs thereof; (v) X 5 is any amino acid, and (vi) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0009] According to one embodiment of the invention there is provided an isolated peptide having a length of 5 amino acids, Formula: X 1 -X 2 -X 3 -X 4 -X 5 It consists of the amino acid sequence represented by SEQ ID NO:5, (i)X 1 and X 3が Any amino acid, (ii) X 2 is proline, or an analog or derivative thereof; (iii) X 4 But not proline, (iv) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0010] According to one embodiment of the invention there is provided an isolated peptide having a length of 7 amino acids, Formula: X 1 -X 2 -X 3 -X 4 -X 5 -X6 -X 7 It consists of the amino acid sequence represented by SEQ ID NO: 6, (i)X 1 , X 5 and X 6 is any amino acid, (ii) X 2 , X 3 and X 7 is proline, or an analog or derivative thereof; (iii)X 4 is not proline, and (iv) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0011] According to one embodiment of the present invention, there is provided a pharmaceutical composition comprising the peptide according to any one of claims 1 to 27 as an active ingredient, and further comprising a physiologically acceptable carrier.

[0012] According to an embodiment of the invention, the derivative of proline is selected from the group consisting of N-methylproline, alpha-methylproline and alpha-aminobutyric acid.

[0013] According to an embodiment of the invention, the peptide is 6 amino acids in length.

[0014] According to an embodiment of the invention, the peptide is X 1 attached to the N-terminus of said amino acid is selected from the group consisting of alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof.

[0015] According to an embodiment of the present invention, the X 1 The amino acid attached to the N-terminus of is leucine, or a derivative or analogue thereof.

[0016] According to an embodiment of the present invention, the X 1 The amino acid attached to the N-terminus of is a D-amino acid.

[0017] According to an embodiment of the invention, the peptide is 7 amino acids in length.

[0018] According to an embodiment of the present invention, X in the formula 4 is alanine, or an analog or derivative thereof.

[0019] According to an embodiment of the present invention, X in the formula 5 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and derivatives or analogs thereof.

[0020] According to an embodiment of the present invention, X 5 is tyrosine.

[0021] According to an embodiment of the invention, the isolated peptide comprises the amino acid sequence shown in SEQ ID NO:4.

[0022] According to an embodiment of the invention, the isolated peptide consists of the amino acid sequence shown in SEQ ID NO:4.

[0023] According to an embodiment of the invention, the peptide comprises the amino acid sequence shown in SEQ ID NO:18.

[0024] According to an embodiment of the invention, the peptide consists of the amino acid sequence shown in SEQ ID NO:18.

[0025] According to an embodiment of the invention, the isolated peptide is 5 amino acids in length.

[0026] According to an embodiment of the present invention, X in the formula 4 is selected from the group consisting of alanine, proline, a derivative or analog of alanine, and a derivative or analog of proline.

[0027] According to an embodiment of the invention, the proline derivative or analogue is selected from the group consisting of N-methylproline, alpha-methylproline and alpha-aminobutyric acid.

[0028] According to an embodiment of the invention, the amino acid sequence comprises the sequence shown in SEQ ID NO:3.

[0029] According to an embodiment of the invention, the isolated peptide consists of the amino acid sequence shown in SEQ ID NO:3, SEQ ID NO:7, or SEQ ID NO:18.

[0030] According to an embodiment of the present invention, X 3 is leucine.

[0031] According to an embodiment of the present invention, X 1 and / or X 3 is a D-amino acid.

[0032] According to an embodiment of the invention, the peptide is a stapled peptide.

[0033] According to an embodiment of the invention, the peptide is a cyclic peptide.

[0034] According to an embodiment of the invention, the order of the sequence is reversed and all amino acids are in the D form.

[0035] According to an embodiment of the invention, the peptide is conjugated to a cell penetrating moiety.

[0036] According to an embodiment of the invention, the cell penetrating moiety is attached to the N-terminus of the peptide.

[0037] According to an embodiment of the invention, the peptide is for the treatment of an inflammatory or degenerative disease.

[0038] According to an embodiment of the present invention, the apoptosis-related disease is an inflammatory disease or a degenerative disease.

[0039] According to an embodiment of the invention, the inflammatory disease is an autoimmune disease.

[0040] According to an embodiment of the present invention, the degenerative disease is a neurodegenerative disease.

[0041] According to an embodiment of the present invention, the apoptosis-related disease is selected from the group consisting of age-related macular degeneration (AMD), retinitis pigmentosa, stroke and myocardial infarction.

[0042] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Although methods and materials similar or equivalent to those described herein can be used to practice or test embodiments of this invention, exemplary methods and / or materials are described below.In case of conflict, the patent specification, including definitions, shall prevail.In addition, the materials, methods, and examples are merely illustrative and are not necessarily intended to be limiting.

[0043] Several embodiments of the present invention are described herein, by way of example only, with reference to the accompanying drawings. Reference will now be made in detail to the drawings, with it being emphasized that the details shown are by way of example and are for the purpose of illustrating detailed descriptions of embodiments of the present invention. Similarly, from a reading of the description together with the drawings, it will become apparent to those skilled in the art how embodiments of the present invention may be practiced. [Brief description of the drawings]

[0044] [Figure 1] 1 is a graph showing the effect of exemplary peptides on spleen weight, spleen cell number, thymus weight and thymus cell number. The peptides used in the screening are PPLPY (SEQ ID NO: 3), LPPLAYP (SEQ ID NO: 4), PLPYP (SEQ ID NO: 9), PPL (SEQ ID NO: 10), PLP (SEQ ID NO: 11), PYP (SEQ ID NO: 12), LPGLPYP (SEQ ID NO: 13), LPPLGYP (SEQ ID NO: 14), LAPLPYP (SEQ ID NO: 15), LPALPYP (SEQ ID NO: 16). [Diagram 2]2 is a graph showing the effect of exemplary peptides on spleen weight, spleen cell number, thymus weight and thymus cell number. The peptides used in the screening are LPPLPYP (SEQ ID NO: 2, control), PPLAYP (SEQ ID NO: 18), LPPLPY (SEQ ID NO: 7), LPPLAYP (SEQ ID NO: 4), PPLPY-NH2 (SEQ ID NO: 19), PPLPY (SEQ ID NO: 3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] The present invention, in some embodiments, relates to compositions and methods of using same for treating inflammatory and autoimmune diseases.

[0046] Before describing at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of elements and / or methods set forth in the following description and / or illustrated in the drawings and / or examples. The invention is capable of other embodiments and of being practiced or carried out in various ways.

[0047] Peptide bonds are found almost exclusively in the trans conformation with a torsion angle omega of 180°, while there is a very limited amount of cis conformation with an omega angle of around 0°. The energy barrier between the trans / cis conformations is about 20 [kcal / mol], with the trans isomer being energetically favored by ~2.5 [kcal / mol]. Among the 20 common amino acids, proline plays a special role. Since the proline peptide bond with the preceding amino acid residue (Xaa-Pro, where Xaa is any amino acid) lacks a hydrogen from the amide group, this peptide bond cannot act as a hydrogen bond donor, and the energy barrier as well as the energy gap are significantly reduced to ~13 and ~0.5 [kcal / mol], respectively [2], and the trans / cis equilibrium is shifted towards the cis conformation. The large change in the omega angle (from 0 to 180) associated with the trans / cis isomerization process of proline is mediated by intra- and intermolecular interactions and has a dramatic impact on the structure-activity relationship of polypeptide chains. Proline isomerization thus emerges as an important component in controlling the activity of many biological processes, especially in short peptides where the cis conformation can occupy more than 30% of the conformational population depending on the immediately preceding residue.

[0048] A multiconformational proline effect is also well-known for proline residues located at the second residue from the N-terminus of a peptide (penultimate proline): Cleavage of the first N-terminal residue from a peptide containing a penultimate proline typically results in a conformational change in the peptide; in a data set of 58 peptides, nearly 80% of the peptides showed this effect [Glover, MS, et al., 2014 J Am Soc Mass Spectrom. 26(3): p. 444-5].

[0049] The proline-rich peptide LPPLPYP (SEQ ID NO: 2), also known as IPL344 and stressin-1, is a short 7-amino acid peptide that protects various cells from proapoptotic pressures and activates the Akt signaling pathway, and is a potential therapeutic candidate for inflammatory and autoimmune diseases.

[0050] Considering the delicate conformational characteristics of proline, we started to investigate whether the trans-proline conformation dominates the functionality of all four proline residues in the LPPLPYP (SEQ ID NO: 2) peptide. Surprisingly, we found that a peptide in which the penultimate proline was replaced by an alanine (SEQ ID NO: 4) significantly reduced dexamethasone-induced spleen and / or thymus weight loss in mice (Figure 1). In stark contrast, replacement of the penultimate proline by a glycine resulted in a peptide that lacked this activity.

[0051] As a result of further investigations aimed at commercializing the present invention, the inventors have found that removal of the first and last amino acids of SEQ ID NO:2 also results in a peptide (having the sequence shown in SEQ ID NO:3) that significantly reduces dexamethasone-induced spleen and / or thymus weight loss in mice.

[0052] The inventors conclude that short peptides based on SEQ ID NOs: 3 and 4 show promising therapeutic effects against inflammatory and autoimmune diseases.

[0053] As a result of further investigations aimed at practical application of the present invention, the inventors have found that a further peptide conforming to the formula shown in SEQ ID NO: 17 (SEQ ID NO: 18) brings about a significant improvement in reducing dexamethasone-induced spleen and / or thymus weight loss in mice (see Figure 2).

[0054] The inventors further demonstrated that exemplary peptides corresponding to any of the disclosed general formulas exhibited significant improvement in reducing dexamethasone-induced spleen and / or thymus weight loss in mice compared to the base peptide (SEQ ID NO:2).

[0055] As used herein, the term "peptide" refers to a polymer of natural or synthetic amino acids and includes native polypeptides (e.g., degradation products, synthetically synthesized polypeptides and / or recombinant polypeptides) as well as peptidomimetics (typically chemically synthesized peptides) and polypeptide analogs, such as peptoids and semipeptoids, that have modifications that, for example, render the peptide more stable in the body or more easily permeable to cells.

[0056] The invention also includes derivatives (having modifications and / or addition of chemical functional groups to the amino acid side chains without chemical alterations to the peptidic backbone) and analogs (having modifications within the peptidic backbone and / or addition of chemical functional groups, e.g., N- or C-terminal modifications, peptide bond modifications, amino acid modifications not defined as "derivatives"), and complexes with other molecular species, e.g., metal ions (e.g., copper, zinc, manganese, magnesium, etc.).

[0057] Such modifications include, but are not limited to, N-terminal modifications, C-terminal modifications, polypeptide bond modifications, and further include, but are not limited to, CH2-NH, CH2-S, CH2-S=O, O=C-NH, CH2-O, CH2-CH2, S=C-NH, CH=CH or CF=CH, backbone modifications and residue modifications. Methods for producing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, CA Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992). The disclosure of this document is incorporated herein by reference as if fully set forth herein. Further details on this subject are described herein.

[0058] The polypeptide bond (-CO-NH-) in the polypeptide may be replaced with, for example, an N-methylated amide bond (-N(CH3)-CO-), an ester bond (-C(=O)-O-), a ketomethylene bond (-CO-CH2-), an α-aza bond (-NH-N(R)-CO-) where R is any alkyl (e.g., methyl), a carba bond (-CH2-NH-), a hydroxyethylene bond (-CH(OH)-CH2-), a thioamide bond (-CS-NH-), an olefinic double bond (-CH=CH-), a retroamide bond (-NH-CO-), a peptide derivative (-N(R)-CH2-CO-) where R is a naturally occurring "normal" side chain on a carbon atom.

[0059] These modifications may occur at any bond along the polypeptide chain, and may occur at multiple (2 to 3) bonds simultaneously.

[0060] The natural aromatic amino acids Trp, Tyr and Phe may be substituted with synthetic non-natural aromatic amino acids such as phenylglycine analogues, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or O-methyl-Tyr.

[0061] Proline may be substituted with synthetic unnatural amino acids such as the derivatives N-methylproline, alpha-methylproline and the analog alpha-aminobutyric acid.

[0062] Other unnatural amino acids are summarized in Table 2 below.

[0063] In addition to the above, the polypeptides of the present invention may contain one or more modified amino acids or one or more non-amino acid monomers (eg, fatty acids, complex carbohydrates, etc.).

[0064] In the present specification and claims, the term "amino acid" or "amino acids" is to be understood to include the 20 naturally occurring amino acids (often post-translationally modified in vivo, e.g., hydroxyproline, phosphoserine, and phosphothreonine), as well as other unusual amino acids (such as, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, norvaline, norleucine, and ornithine). Additionally, the term "amino acid" includes both D- and L-amino acids (stereoisomers).

[0065] Tables 1 and 2 below list naturally occurring amino acids (Table 1) and non-conventional or modified amino acids (Table 2) that can be used with some embodiments of the present invention.

[0066] [Table 1]

[0067] [Table 2-1]

[0068] [Table 2-2]

[0069] [Table 2-3]

[0070] The amino acids of the peptides of the present invention may be substituted conservatively or non-conservatively.

[0071] The term "conservative substitution" as used herein refers to the replacement of an amino acid present in the native sequence of a peptide with a natural or non-natural amino acid mimetic or a peptidomimetic having similar steric properties. If the side chain of the native amino acid to be replaced is polar or hydrophobic, the conservative substitution should be with a natural amino acid, a non-natural amino acid, or a peptidomimetic moiety that is polar or hydrophobic (in addition to having the same steric properties as the side chain of the substituted amino acid).

[0072] Since natural amino acids are generally classified according to their properties, conservative substitutions with natural amino acids can be easily determined, taking into account that in the present invention, the substitution of a charged amino acid with a sterically similar uncharged amino acid is considered to be a conservative substitution.

[0073] It is also possible to use amino acid analogues (synthetic amino acids) well known in the art to make conservative substitutions with non-natural amino acids. Peptide mimetics of natural amino acids are well described in the literature known to those skilled in the art.

[0074] When making a conservative substitution, the substituting amino acid should have the same or a similar substituent in the side chain as the original amino acid.

[0075] As used herein, the phrase "non-conservative substitution" refers to the replacement of an amino acid present in a parent sequence with another natural or unnatural amino acid that has different electrochemical and / or steric properties. Thus, the side chain of the substituting amino acid may have a functional group that is significantly larger (or smaller) than the side chain of the original amino acid being replaced and / or has significantly different electronic properties compared to the amino acid being replaced. Examples of this type of non-conservative substitution include the replacement of alanine with phenylalanine or cyclohexylmethylglycine, glycine with isoleucine, or aspartic acid with -NH-CH[(-CH 2 ) 5 These non-conservative substitutions which are within the scope of the present invention are those which still constitute a peptide having antibacterial properties.

[0076] As mentioned above, the N- and C-termini of the peptide of the present invention can be protected by functional groups. Suitable functional groups are described in Green and Wuts, "Protecting Groups in Organic Synthesis", John Wiley and Sons, Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. Preferred protecting groups are those that facilitate the transport of the compound attached thereto into cells, for example by reducing the hydrophilicity of the compound and increasing the lipophilicity of the compound.

[0077] These moieties are cleaved in vivo by hydrolysis or enzymes within the cell. Hydroxyl protecting groups include ester, carbonate and carbamate protecting groups. Amine protecting groups include alkoxy and aryloxycarbonyl groups as described above for N-terminal protecting groups. Carboxylic acid protecting groups include aliphatic, benzyl and aryl esters as described above for C-terminal protecting groups. In one embodiment, the carboxylic acid group of the side chain of one or more glutamic or aspartic acid residues in the peptide of the invention is preferably protected with a methyl, ethyl, benzyl or substituted benzyl ester.

[0078] Examples of N-terminal protecting groups include acyl groups (-CO-R1) and alkoxycarbonyl or aryloxycarbonyl groups (-CO-O-R1), where R1 is an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group. Specific examples of acyl groups include acetyl, (ethyl)-CO-, n-propyl-CO-, iso-propyl-CO-, n-butyl-CO-, sec-butyl-CO-, t-butyl-CO-, hexyl, lauroyl, palmitoyl, myristoyl, stearyl, oleoylphenyl-CO-, substituted phenyl-CO-, benzyl-CO- and (substituted benzyl)-CO-. Examples of alkoxycarbonyl and aryloxycarbonyl groups include CH3-O-CO-, (ethyl)-O-CO-, n-propyl-O-CO-, iso-propyl-O-CO-, n-butyl-O-CO-, sec-butyl-O-CO-, t-butyl-O-CO-, phenyl-O-CO-, substituted phenyl-O-CO- and benzyl-O-CO-, (substituted benzyl)-O-CO-, adamantane, naphthalene, myristole, toluene, biphenyl, cinnamoyl, nitrobenzoyl, toluoyl, furoyl, benzoyl, cyclohexane, norbornane, Z-caproic acid. To facilitate N-acylation, one to four glycine residues can be present at the N-terminus of the molecule.

[0079] The carboxyl group at the C-terminus of the compound can be, for example, an amide (i.e., the hydroxyl group at the C-terminus can be -NH 2 , -NHR 2 and -NR 2 R 3 ) or ester (i.e., the C-terminal hydroxyl group is replaced with -OR 2 (replaced by R). 2 and R 3 are independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group. 2 and R 3can be combined with the nitrogen atom to form a C4-C8 heterocyclic ring having 0-2 additional heteroatoms such as nitrogen, oxygen or sulfur. Examples of suitable heterocyclic rings include piperidinyl, pyrrolidinyl, morpholino, thiomorpholino or piperazinyl. Examples of C-terminal protecting groups include -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NH(ethyl), -N(ethyl) 2 , -N(methyl)(ethyl), -NH(benzyl), -N(C1-C4 alkyl)(benzyl), -NH(phenyl), -N(C1-C4 alkyl)(phenyl), -OCH 3 , -O-(ethyl), -O-(n-propyl), -O-(n-butyl), -O-(iso-propyl), -O-(sec-butyl), -O-(t-butyl), -O-benzyl and -O-phenyl.

[0080] The peptides of the present invention may also include non-amino acid moieties, such as hydrophobic moieties (various linear, branched, cyclic, polycyclic or heterocyclic hydrocarbons and hydrocarbon derivatives) attached to the peptide, non-peptide permeabilizing agents, various protecting groups (particularly those where the compound is linear and attached to the termini of the compound to reduce degradation). Chemical (non-amino acid) groups present in the compound may also be included to improve various physiological properties, such as reduced degradation or clearance, reduced repulsion by various cellular pumps, improved immunogenic activity, improved various modes of administration (such as attachment of various sequences to allow passage through various barriers, such as the intestine), improved specificity, improved affinity, reduced toxicity, etc.

[0081] The attachment of the amino acid sequence components of the peptides of the invention to other non-amino acid agents can be by covalent attachment, by non-covalent complexation (e.g., complexation with hydrophobic polymers that degrade or cleave to generate compounds that can be released over time), or by encapsulation of the amino acid portion of the peptide in liposomes or micelles to generate the final peptides of the invention. These associations can also be by encapsulation of the amino acid sequence in other components (liposomes, micelles) or by impregnation of the amino acid sequence in polymers to generate the final peptides of the invention.

[0082] According to a particular embodiment, the peptide is conjugated to a cell-penetrating moiety.

[0083] As used herein, the term "cell-penetrating moiety" refers to a moiety (e.g., a lipid, such as palmitic acid) that facilitates the movement of an attached peptide through a cell membrane. In certain embodiments, the cell-penetrating moiety is not a peptide moiety. The moiety can be attached at the N-terminus or C-terminus.

[0084] The peptides of the invention may be linear or cyclic (cyclization may improve stability). Cyclization may be accomplished by means known in the art. If the compound is composed primarily of amino acids, cyclization may be via N-to-C terminus, N-to-side chain and N-to-main chain, C-to-side chain, C-to-main chain, side chain-to-main chain and side chain-to-side chain, as well as main chain-to-main chain cyclization. Peptides may also be cyclized by non-amino acid organic moieties contained in the peptide.

[0085] The inventors further contemplate stapled peptides.

[0086] As used herein, the term "stapled peptide" refers to a peptide having a selected number of standard or non-standard amino acids and further having at least two moieties capable of participating in a reaction that promotes the formation of a carbon-carbon bond that upon contact with a reagent forms at least one crosslink between the at least two moieties, e.g., to modulate the stability of the peptide.

[0087] The term "stapling" as used herein refers to the introduction into a peptide of at least two moieties capable of participating in a reaction that promotes the formation of a carbon-carbon bond, which upon contact with a reagent forms at least one crosslink between the at least two moieties. Stapling imposes constraints on the secondary structure, e.g., an alpha helical structure. The length and geometry of the crosslinks can be optimized to improve the yield of the desired secondary structure content. The imposed constraints can, for example, prevent the secondary structure from unfolding and / or reinforce the shape of the secondary structure. A secondary structure that is prevented from unfolding is, for example, more stable.

[0088] The peptides of the present invention can be biochemically synthesized by using standard solid-phase techniques, including exclusive solid-phase synthesis, partial solid-phase synthesis, fragment condensation, and classical liquid-phase synthesis. Solid-phase polypeptide synthesis procedures are well known in the art and are further described in John Morrow Stewart and Janis Dillaha Young, Solid Phase Polypeptide Syntheses (2nd Ed., Pierce Chemical Company, 1984).

[0089] Large scale peptide synthesis is described in Andersson Biopolymers 2000;55(3):227-50.

[0090] Synthetic peptides can be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. NY] and their composition can be confirmed by amino acid sequencing.

[0091] The peptides of the present invention may be produced using recombinant techniques. To produce the peptides of the present invention using recombinant techniques, a polynucleotide encoding the peptide of the present invention is ligated into a nucleic acid expression vector that contains a polynucleotide sequence under the transcriptional control of a cis-regulatory sequence (e.g., a promoter sequence) suitable for directing constitutive, tissue-specific, or inducible transcription of the polypeptide of the present invention in a host cell.

[0092] In addition to being synthesized in a host cell, the peptides of the invention can also be synthesized using in vitro expression systems, the methods of which are well known in the art and the components of such systems are commercially available.

[0093] The peptides described herein can, for example, reduce dexamethasone-induced spleen and / or thymus weight loss in mice following 100 μg dexamethasone injection (IP).

[0094] In another embodiment, the peptides described herein are capable of interfering with and blocking both the secretion of TNF-α and the secretion of IL-6 in response to innate activators, such as lipopolysaccharide (LPS) and CpG oligonucleotides, by macrophage cells.

[0095] Additionally or alternatively, the peptides described herein can reduce, prevent or inhibit apoptosis in eukaryotic cells. Regardless of the mechanism by which the peptides of the invention mediate the stress response, and without being bound by any theory or mechanism of action, it is hypothesized that the peptides are capable of binding to p53 and thus preventing p53 from binding to damaged DNA. The peptides can be tested by analyzing their ability to inhibit the response of L12 cell lines (which lack endogenous p53 activity and are stably transformed with a p53 gene or a control vector) to high temperature. In these cells, p53 activity in response to high temperature induces inhibition of growth and cell survival, but not apoptosis (as described in WO 2012 / 160563, the contents of which are incorporated herein by reference).

[0096] How to measure apoptosis: Apoptosis is an active genetically-driven process of cell self-destruction, associated with characteristic morphological and biochemical changes. Condensation and fragmentation of the nucleus and cytoplasm into membrane-bound apoptotic bodies in dying cells is a typical feature of apoptosis. Another characteristic of apoptotic cell death is the degradation of chromosomal DNA into oligonucleosomal fragments after activation of specific nucleases. "Inhibition of apoptosis" or "inhibition of apoptotic activity" refers to any reduction in the number of cells undergoing apoptosis relative to untreated controls (i.e., cells not exposed to the peptides of the invention). Preferably, the reduction is at least 25%, more preferably, the reduction is at least 50%, and most preferably, the reduction is at least 1-fold.

[0097] Flow cytometry offers a wide variety of possibilities for measuring apoptosis: different techniques have been established and implemented, some of which stain the cell surface and some of which stain intracellularly.

[0098] One of the early methods was to stain with DNA-specific fluorescent dyes (e.g., propidium iodide [PI], ethidium bromide [EtBr]) in response to the finding that apoptotic cells are shrunken and have a higher degree of intracellular granularity. As soon as a lethal hit is induced, DNA begins to change its appearance. Apoptotic DNA does not consist only of fragmented DNA (visible on agarose gels as short bands called DNA ladders), but is partially digested to single nucleotides, leaving less DNA for fluorescent dyes such as PI or EtBr to stain (Nicoletti et al., 1991). This allows the use of FACScan TM This is typically observed as a left shift, called the sub-G1 peak, in the fluorescent dye detection channel of the GFP (Becton Dickinson, USA).

[0099] Another method is terminal deoxynucleotidyl transferase (TdT)-mediated end labeling (TUNEL) of DNA strand breaks. The TUNEL method detects DNA strand breaks in cells undergoing apoptosis. TdT is an enzyme that catalyzes the addition of deoxyribonucleotide triphosphates to the 3'-OH termini of double-stranded or single-stranded DNA. Unlike normal cells, the nuclei of apoptotic cells incorporate exogenous nucleotides (dUTP)-DIG in the presence of TdT. Anti-DIG antibody fragments conjugated with fluorescent dyes allow visualization of apoptotic cells. An increase in apoptotic cells leads to more DNA fragments and, consequently, brighter fluorescence. The advantage of this method is its very high specificity (Gavrieli et al., 1992). The disadvantage of this method is that it is expensive and time-intensive, so it can only be used on small sample sets. It is therefore not adaptable to large screening programs.

[0100] The loss of plasma membrane polarity in early apoptosis and the increased presentation of phosphatidylserine (PS) on the outer surface of the plasma membrane led to a further novel method. Annexin V is a calcium-dependent phospholipid-binding protein with high affinity for PS. During early and mid-stages of apoptosis, plasma membrane integrity is maintained. Early and mid-stage apoptotic cells show increased Annexin-FITC binding and are primarily PI-negative staining. Late apoptotic stage and necrotic cells are double positive due to the presentation of PS on the surface and PI staining of intracellular nucleic acids due to membrane disruption. This method is also expensive and laborious.

[0101] Other methods for measuring apoptosis in vivo and in vitro are disclosed in US Pat. Nos. 6,726,895 and 6,723,567.

[0102] Thus, according to a first aspect of the invention there is provided an isolated peptide having a length of six amino acids or less, comprising: Formula: X 1 -X 2 -X 3 -X 4 -X 5 Contains the amino acid sequence represented by SEQ ID NO:1, (i)X 1 is proline, or an analog or derivative thereof; (ii) X 2 is proline, or an analog or derivative thereof; (iii)X 3 is selected from the group consisting of alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof; (iv) X 4 is selected from the group consisting of alanine, valine, serine, proline, and derivatives or analogs thereof; (v) X 5 is any amino acid, and (vi) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0103] Peptides of this embodiment may be 5 or 6 amino acids in length.

[0104] X 1 and X 2 and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 3 and X 4 It is preferred to select the amino acids such that the peptide bond between is in the trans conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted towards the trans conformation.

[0105] Methods for examining the cis / trans conformation of peptide bonds are known in the art and include, for example, NMR.

[0106] In one embodiment, X 4 is selected from the group consisting of alanine, proline, a derivative or analog of alanine, and a derivative or analog of proline.

[0107] According to a particular embodiment, the derivative or analogue of proline is N-methylproline, alpha-methylproline or α-aminobutyric acid.

[0108] In one embodiment, the peptide comprises the sequence shown in SEQ ID NO:3 (PPLPY).

[0109] In another embodiment, the peptide consists of the sequence shown in SEQ ID NO:3 (PPLPY).

[0110] In another embodiment, the peptide consists of the sequence shown in SEQ ID NO:7 (LPPLPY).

[0111] In certain embodiments, X 1 and / or X 3 may be D amino acids, for example the peptide shown in SEQ ID NO:20 (d-LPPLPY).

[0112] According to another aspect of the invention, there is provided an isolated peptide having a length of 10 amino acids or less, comprising: Formula: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 Contains the amino acid sequence represented by SEQ ID NO: 17, (i)X 1 is proline, or an analog or derivative thereof; (ii) X 2 is proline or an analog thereof, (iii)X 3 is selected from the group consisting of alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof; (iv) X 4 is selected from the group consisting of alanine, valine, serine, and derivatives or analogs thereof; (v) X 5 is any amino acid, (vi) X 6 is proline, or an analog or derivative thereof, and (vii) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0113] X 1 and X 2and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 3 and X 4 and the peptide bond between X is in a trans conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the trans conformation, and X 5 and X 6 It is preferred to select amino acids such that the peptide bond between is in the cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted towards the cis conformation.

[0114] In one embodiment, the peptides according to this aspect of the invention are 6 amino acids in length.

[0115] An example of such a peptide is SEQ ID NO: 18 (PPLAYP).

[0116] Preferred unnatural amino acids that can be used to replace proline include, but are not limited to, N-methylproline, alpha-methylproline, and α-aminobutyric acid.

[0117] The present inventors have identified X in SEQ ID NO:17. 1 We considered attaching an additional amino acid to the N-terminus of

[0118] The additional amino acid is the amino acid and X. 1 and are preferably selected such that the peptide bond between is in the cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted towards the cis conformation.

[0119] Candidate amino acids include, but are not limited to, alanine, valine, leucine, cysteine, isoleucine, methionine, and derivatives or analogs thereof.

[0120] In certain embodiments, X 1 The additional amino acid attached to the N-terminus of is leucine, or a derivative or analogue thereof.

[0121] In a further embodiment, X 1 The additional amino acid attached to the N-terminus of is a D-amino acid.

[0122] Thus, the inventors contemplated a peptide having seven amino acids and comprising the formula shown in SEQ ID NO:17.

[0123] According to a particular embodiment, X 4 is alanine, or an analog or derivative thereof.

[0124] In yet another embodiment, X 5 is selected from the group consisting of tyrosine, phenylalanine, tryptophan, and derivatives or analogs thereof.

[0125] X 5 One example of an amino acid that may be considered is tyrosine.

[0126] X 3 One example of an amino acid that may be considered is leucine.

[0127] A peptide according to this aspect of the invention may comprise the amino acid sequence (LPPLAYP) shown in SEQ ID NO: 4. Such peptides may be 7, 8, 9 or 10 amino acids.

[0128] The peptide of this aspect of the present invention may consist of the amino acid sequence shown in SEQ ID NO:4.

[0129] In the peptide of this aspect of the present invention, X 1and / or X 3 and / or X 5 can also be a D amino acid, for example, d-LPPLAYP (SEQ ID NO: 21).

[0130] For any of the peptides described herein, the present invention contemplates retro-inverso peptides, which are protease resistant and consist of D-amino acids in reverse order, resulting in an altered peptide backbone but unchanged side chain configuration.

[0131] According to yet another aspect of the invention there is provided an isolated peptide having a length of 5 amino acids, Formula: X 1 -X 2 -X 3 -X 4 -X 5 It consists of the amino acid sequence represented by SEQ ID NO:5, (i)X 1 and X 3が Any amino acid, (ii) X 2 is proline, or an analog or derivative thereof; (iii) X 4 But not proline, (iv) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0132] X 1 and X 2 and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 3 and X 4 It is preferred to select the amino acids such that the peptide bond between is in the trans conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted towards the trans conformation.

[0133] According to yet another aspect of the invention there is provided an isolated peptide having a length of 7 amino acids, comprising: Formula: X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 It consists of the amino acid sequence represented by SEQ ID NO: 6, (i)X 1 , X 5 and X 6 is any amino acid, (ii) X 2 , X 3 and X 7 is proline, or an analog or derivative thereof; (iii) X 4 is not proline, and (iv) An isolated peptide is provided that is capable of reducing dexamethasone-induced spleen and / or thymus weight loss in mice.

[0134] X 1 and X 2 and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 2 and X 3 and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 6 and X 7 and the peptide bond between X is in a cis conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted to the cis conformation, and X 4 and X 5It is preferred to select the amino acids such that the peptide bond between is in the trans conformation (for at least 50% of the time, at least 60% of the time, at least 70% of the time, at least 80% of the time, or at least 90% of the time), i.e., the equilibrium is shifted towards the trans conformation.

[0135] The peptides described herein can be used to treat a myriad of conditions associated with stress-related responses, including pathological conditions such as neurodegenerative diseases (e.g., stroke, Parkinson's disease, and Alzheimer's disease), myocardial infarction, exposure to radiation or chemotherapy drugs, inflammatory diseases, trauma (e.g., burns and central nervous system injuries), cellular senescence, hyperthermia, stroke, hypoxia (e.g., ischemia and seizures), and the condition of transplant tissues and organs prior to transplantation.

[0136] These conditions also include autoimmune diseases, characterized by the immune state of an individual against at least one normal component of the body. Such phenomena are found in particular, but not limited to, the following pathologies: SLE (systemic lupus erythematosus), Gougelot-Sjogren's syndrome (or Sjogren's disease) and infections associated with rheumatic polyarthritis, as well as sarcoidosis and osteopenia, spondyloarthritis, scleroderma, multiple sclerosis, amyotrophic lateral sclerosis (ALS), hyperthyroidism, Addison's disease, autoimmune hemolytic anemia, Crohn's disease, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, idiopathic dental pulp bleeding, insulin-dependent diabetes mellitus, myasthenia, pemphigus vulgaris, pernicious anemia, poststreptococcal glomerulonephritis, psoriasis and idiopathic infertility, as well as immediate or delayed phenomena during graft rejection and graft-versus-host disease. In one particular embodiment, the peptides of the invention are useful for the treatment of multiple sclerosis, hi another embodiment, the peptides of the invention are useful for the treatment of ischemia or myocardial infarction.

[0137] Other diseases contemplated in the present invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, secondary degeneration after trauma, stroke, CNS poisoning, glaucoma, macular degeneration, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, autoimmune uveitis, graft versus host disease, graft rejection, arthritis, systemic inflammatory response syndrome (SIRS), inflammatory bowel disease (IBD), adult respiratory distress syndrome (ARDS), psoriasis, atherosclerosis, myocardial infarction, radiation sickness, hyperthermia, hypoxia, fulminant hepatitis, renal failure, infertility, and many others.

[0138] The phenomenon of graft rejection is the immune state of an individual against foreign elements (body fluids such as blood, cerebrospinal fluid, cells, tissues, organs, antibodies, etc.) that have been intentionally transplanted into the patient.

[0139] As used herein, the terms "degenerative disorder," "degenerative disease," and "degenerative condition" refer to any disorder, disease, or condition characterized by inappropriate cell proliferation or inappropriate cell death, or possibly both, or abnormal or unregulated apoptosis, including conditions in which excessive apoptosis, even if appropriate and controlled at the level of single cells, is associated with organ dysfunction or failure.

[0140] In one embodiment, the peptides are useful for preventing cell death of non-malignant tissue or cells in a subject having a neoplastic disease and undergoing chemotherapy and / or radiation therapy for the treatment of cancer.

[0141] As used herein, the terms "inflammatory disease" and "inflammatory condition" refer to any disease or condition in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue destruction, or loss of tissue function.

[0142] In one embodiment, the inflammatory disease or condition is an autoimmune disease.

[0143] In another embodiment, the inflammatory disease or condition has an etiology associated with the production of at least one pro-inflammatory cytokine selected from IL-6 and TNF-α.

[0144] In another embodiment, the disease or condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, secondary degeneration after trauma, stroke, CNS poisoning, glaucoma, macular degeneration, myocardial infarction, radiation sickness, hyperthermia, hypoxia, fulminant hepatitis, renal failure and infertility.

[0145] In yet another embodiment, the disease includes retinitis pigmentosa and macular degeneration.

[0146] In another embodiment, the disease comprises stroke or myocardial infarction.

[0147] The peptides of some embodiments of the present invention can be administered to an organism by themselves or as part of a pharmaceutical composition in which the peptide is mixed with a suitable carrier or excipient.

[0148] As used herein, a "pharmaceutical composition" refers to a formulation that contains one or more active ingredients as described herein, together with other chemical components, such as physiologically suitable carriers or excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0149] As used herein, the term "active material" refers to a peptide that can be responsible for a biological effect.

[0150] Hereinafter, the terms "physiologically acceptable carrier" and "pharmaceutical acceptable carrier", which can be used interchangeably, refer to a carrier or diluent that does not cause significant irritation to an organism and does not abolish the biological activity and properties of the administered compound. Adjuvants are included in these terms.

[0151] The preparation of pharmaceutical compositions containing peptides or polypeptides as active materials is well known in the art. Typically, such compositions are prepared as liquid solutions or suspensions so that they are indictable, but they can also be prepared in solid form that can be suspended or solubilized prior to injection. The formulations can also be in the form of emulsions. The active therapeutic material is mixed with inorganic and / or organic carriers that are pharma- ceutical acceptable and compatible with the active material. Carriers are pharma-ceutical acceptable excipients (vehicles) that contain some inactive material when added to a pharmaceutical composition to ensure a suitable consistency or form for the composition. Suitable carriers are, for example, water, saline, dextrose, glycerin, ethanol, or combinations thereof. In addition, if desired, the composition can contain small amounts of auxiliary substances that enhance the effectiveness of the active material, such as wetting or emulsifying agents, as well as pH buffering agents.

[0152] Toxicity and therapeutic efficacy of the peptides described herein can be determined by standard pharmaceutical techniques in cultured cells or experimental animals, e.g., IC 50 (concentration producing 50% inhibition) and LD 50 The lethal dose (the dose that produces death in 50% of the test animals) can be determined by determining the lethal dose. The data obtained from such cell culture assays and animal studies can be used to design a range of dosages for use in humans. The dosage may vary depending on the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975).

[0153] The amount of active ingredient used in the composition for administration of the present invention is an amount effective for the specific active ingredient to achieve its purpose against the target indication. The amount of active ingredient in the composition is typically a pharmacologic, biological, therapeutic or chemically effective amount. However, when the composition is used as a dosage unit form, a smaller amount can be used. Because, in the case of dosage unit form, a single composition contains multiple compounds or active ingredients, or contains a fraction of a pharmacologic, biological, therapeutic or chemically effective amount. And, the total effective amount can be administered by the cumulative unit containing an effective amount of active ingredient in total.

[0154] A therapeutically effective amount of the peptide of the present invention is an amount that can exert anti-apoptotic and / or anti-inflammatory activity when administered to a patient. Assays for detecting the anti-apoptotic activity of the peptide of the present invention include, but are not limited to, DNA staining with specific fluorescent dyes such as propidium iodide and ethidium bromide, Annexin V assay, and TUNEL assay. Some non-limiting examples of such assays are provided in the Examples below. Assays for detecting the anti-inflammatory activity of peptides are also known in the art.

[0155] The appropriate dosage of the peptide of the present invention varies depending on the administration route, age, body weight, sex, and condition of the patient, and must ultimately be determined by a physician; however, the appropriate dosage for an adult human is usually between about 0.2 to 2000 mg / kg body weight, preferably between about 2 to 200 mg / kg.

[0156] The pharmaceutical compositions of the invention comprise one or more compounds of the invention and one or more excipients or diluents. One embodiment is one or more compounds, or a solvate or salt of said compounds.

[0157] As used herein, "pharmaceutically acceptable salts" refer to salts that are substantially non-toxic to living organisms. Exemplary pharmaceutically acceptable salts include salts prepared by reacting the compounds of the present invention with pharmaceutically acceptable mineral or organic acids. These salts are also known as acid addition salts.

[0158] Compositions comprising the compounds and active ingredients are useful for delivery of the active ingredient to a selected biological system and for achieving increased or improved bioavailability of the active ingredient compared to administration of the active ingredient without a delivery agent. Improved delivery can be achieved by delivering more active ingredient in a period of time, or by delivering the active ingredient within a period of time (e.g., faster or slower delivery) or over a period of time (e.g., sustained delivery).

[0159] Thus, pharmaceutical compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliaries that aid in the processing of the active ingredient into a pharma- ceutically usable preparation. The appropriate formulation depends on the route of administration selected.

[0160] The pharmaceutical compositions may be administered locally or systemically by any suitable conventional route, including, but not limited to, oral, intraperitoneal, parenteral, intravenous, intramuscular, subcutaneous, transdermal, intrathecal, topical, rectal, buccal, inhalation, or nasal.

[0161] For injection, the active ingredients of the pharmaceutical composition can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, a penetrant appropriate to the barrier to be permeated is used in the formulation. Such penetrants, for example, DMSO and polyethylene glycol, are generally known in the art.

[0162] Pharmaceutical compositions that can be used orally include push-fit capsules made of gelatin and sealed soft capsules made of gelatin and a plasticizer such as glycerol or sorbitol. Push-fit capsules may contain the active ingredient in a mixture with a filler such as lactose, a binder such as starch, a lubricant such as talc or magnesium stearate, and optional stabilizers.

[0163] In soft capsules, the active ingredient may be dissolved or suspended in a suitable liquid, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Additionally, stabilizers may be added. All formulations for oral administration should be in a dosage form appropriate for the chosen route of administration.

[0164] Alternatively, the compounds of the present invention can be incorporated into oral liquid preparations, such as, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs. Furthermore, formulations containing these compounds can be provided as a dry product, which is made up of water or other suitable vehicle before use. Such liquid preparations may contain suspending agents such as sorbitol syrup, methylcellulose, glucose / sugar syrup, gelatin, hydroxymethylcellulose, carboxymethylcellulose, aluminum stearate gel and hydrogenated edible fats and oils, emulsifying agents such as lecithin, sorbitan monooleate or acacia, non-aqueous vehicles (including edible oils) such as almond oil, coconut oil, oily esters, propylene glycol and ethyl alcohol, and conventional additives such as methyl or propyl p-hydroxybenzoates and sorbic acid.

[0165] For administration by inhalation, the peptides used according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or nebulizers using a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated to contain a powder mix of the peptide and a suitable powder base, such as lactose or starch.

[0166] The pharmaceutical compositions of the present invention are also useful for topical and intralesional administration. As used herein, "topical" means "relating to a particular surface area," e.g., skin and mucous membranes, and a topical agent administered to an area of ​​a surface only acts on the area to which it is administered. Formulations of peptides / peptide analogs can be administered locally as gels, ointments, creams, emulsions, sustained release formulations including transdermal patches, and may include liposomes and other pharma- ceutically acceptable carriers suitable for topical administration of drugs. The pharmaceutical compositions described herein may further include suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycol.

[0167] The compositions of the invention can be provided in a pack or dispenser device, such as an FDA approved kit, which can contain one or more unit dosage forms containing the active ingredient, if desired. The pack can, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration. The pack or dispenser can also be accompanied by a notice associated with the container in a format prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, which notice reflects the approval by the agency of the composition's form and administration to humans or animals. Such notice can, for example, be of the label approved by the U.S. Food and Drug Administration for prescription drugs, or of an approved product insert. Compositions comprising the preparations of the invention formulated in a compatible pharmaceutical carrier, as further detailed above, can also be prepared, placed in a suitable container, and labeled for the treatment of an indicated condition.

[0168] As used herein, the term "about" means ±10%.

[0169] The terms "comprises," "comprising," "includes," "including," "having" and conjugations thereof mean "including but not limited to."

[0170] The term "consisting of" means "including and limited to."

[0171] The term "consisting essentially of" means that a composition, method, or structure may include additional ingredients, steps, and / or moieties, provided that the additional ingredients, steps, and / or moieties do not materially alter the basic and novel characteristics of the claimed composition, method, or structure.

[0172] As used herein, the singular forms "a," "an," and "the" include the plural unless the context clearly indicates otherwise. For example, "a compound" or "at least one compound" includes a plurality of compounds, and may also include mixtures thereof.

[0173] Throughout this application, various embodiments of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity, and is not an inflexible limitation of the scope of the invention. Thus, the description of a range should be considered to specifically disclose all of the possible subranges, as well as each individual numerical value within that range. For example, the description of a range such as 1 to 6 is intended to specifically disclose not only the subranges 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., but also each individual numerical value within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the magnitude of the range.

[0174] Whenever a numerical range is given herein, it is intended to include any recited number (fractional or integer) within the range given. The phrases "range between" a first designated number and a second designated number and "range from" a first designated number to a second designated number are used interchangeably herein and are intended to include the first designated number and the second designated number, and all fractional and integer numbers therebetween.

[0175] As used herein, the term "method" means manner, means, techniques, and procedures for accomplishing a given task, including, but not limited to, those known to practitioners in the chemical, pharmacological, biological, biochemical, and medical fields or that can be readily developed by practitioners from known manners, means, techniques, and procedures.

[0176] As used herein, the term "treating" includes arresting, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating a clinical or cosmetic symptom of a condition, or substantially preventing the worsening of a clinical or cosmetic symptom of a condition.

[0177] It will be understood that certain features of the invention that are, for clarity, described in the context of separate embodiments, may also be provided in a single embodiment in any combination of those features. Conversely, several features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or with respect to other described embodiments as appropriate. Certain features described in the context of various embodiments should not be construed as essential to that embodiment, unless the particular embodiment is inoperable without that element.

[0178] As noted above, various embodiments and aspects of the present invention as described and claimed herein find experimental support in the following examples. EXAMPLES

[0179] Reference is now made to the following examples which, together with the above descriptions, illustrate the invention without limiting it.

[0180] In general, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are fully explained in the literature, see, e.g., "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, RM, ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York. (1998); methods described in U.S. Patent Nos. 4,666,828, 4,683,202, 4,801,531, 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, JE, ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, NY (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan JE, ed. (1994); Stites et al.(eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", WH Freeman and Co., New York (1980), available immunoassays have been described extensively in the patent and scientific literature (see, e.g., U.S. Pat. Nos. 3,791,932, 3,839,153, 3,850,752, 3,850,578, 3,853,987, 3,867,517, 3,879,262, 3,901,654, 3,935,074, 3,984,533, 3,996,345, 4,034,074, 4,098,876, 4,879,219, 5,011,771, and 5,281,521), "Oligonucleotide Synthesis" Gait, MJ, ed. (1984); "Nucleic Acid "Hybridization" Hames, BD, and Higgins SJ, eds. (1985); "Transcription and Translation" Hames, BD, and Higgins SJ, Eds. (1984); "Animal Cell Culture" Freshney, RI, ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996), all of which are incorporated herein by reference. Other general references are provided throughout this document. The procedures described therein are believed to be well known in the art and are provided for the convenience of the reader. All of the information contained therein is incorporated herein by reference.

[0181] Example 1 Dexamethasone is a corticosteroid that induces apoptosis in immune cells and lymphoid myeloid tissues. BALB / c mice were used to study the ability of candidate peptides to rescue lymphocytes from apoptosis. Mice were injected IP with 100 μg dexamethasone. Dexamethasone-treated mice received IV injections of candidate peptides (250 or 400 μg peptide / mouse) immediately and 24 hours after dexamethasone treatment. Mice were sacrificed 48 hours after the first treatment. Spleen and thymus were weighed and total cell counts were determined in both tissues.

[0182] The peptides used in the screening are as follows: PPLPY - SEQ ID NO:3 LPPLAYP - sequence number 4 PLPYP - SEQ ID NO: 9 PPL - SEQ ID NO:10 PLP - SEQ ID NO:11 PYP - SEQ ID NO:12 LPGLPYP - SEQ ID NO: 13 LPPLGYP - SEQ ID NO: 14 LAPLPYP - SEQ ID NO: 15 LPALPYP - SEQ ID NO: 16

[0183] result Dexamethasone-induced reduction in spleen and thymus weights and spleen cell count was about 50%. Thymocyte count was reduced by nearly 80% compared to normal mice. Two peptides showed a significant reducing effect on cell count reduction as well as spleen and thymus weight reduction - SEQ ID NO: 3 and SEQ ID NO: 4 (see Figure 1). There was no difference between the two therapeutic doses (250 or 400 μg / mouse).

[0184] Example 2 BALB / c mice were used to test the ability of candidate peptides to rescue lymphocytes from apoptosis. Mice were injected IP with 100 μg dexamethasone. Dexamethasone-treated mice received IV injections of candidate peptides (200 μg peptide / mouse) immediately and 24 hours after dexamethasone treatment. Mice were sacrificed 48 hours after the first treatment. Spleen and thymus were weighed and total cell counts were determined in both tissues.

[0185] The peptides used in the screening are as follows: LPPLPYP - SEQ ID NO:2 (control) PPLAYP - sequence number 18 LPPLPY - SEQ ID NO:7 LPPLAYP - sequence number 4 PPLPY - SEQ ID NO:3 PPLPY-NH 2 - SEQ ID NO:19

[0186] result The results are shown in Figure 2. Each of the peptides tested showed improvement over the control peptide (SEQ ID NO:2).

[0187] While the present invention has been described in conjunction with specific embodiments thereof, many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the appended claims.

[0188] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, and patent application was specifically and individually incorporated herein by reference. In addition, citation or identification of any reference in this application should not be construed as an admission that such reference is available as prior art to the present invention. Nor should it be necessarily construed as limiting, to the extent that section headings are used.

[0189] Furthermore, the contents of the basic application of this application are incorporated herein by reference in their entirety. [Sequence List Free Text]

[0190] SEQ ID NO: 1: A peptide, in which X at positions 1-2 is proline or an analog or derivative thereof, X at position 3 is alanine, valine, leucine, cysteine, isoleucine, methionine, or a derivative or analog thereof, X at position 4 is alanine, valine, serine, proline, or a derivative or analog thereof, and X at position 5 can be any amino acid. SEQ ID NO: 2: Amino acid sequence of streptin-1 SEQ ID NO: 3: synthetic peptide SEQ ID NO: 4: Synthetic peptide SEQ ID NO:5: Synthetic peptide, where Xaa at position 1 can be any naturally occurring amino acid, X2 at position 2 is proline or an analogue or derivative thereof, Xaa at position 3 can be any naturally occurring amino acid, X at position 4 is not proline, and Xaa at position 5 can be any naturally occurring amino acid. SEQ ID NO:6: A synthetic peptide, in which Xaa at position 1 can be any naturally occurring amino acid, X at positions 2-3 is proline or an analogue or derivative thereof, X at position 4 is not proline, Xaa at positions 5-6 can be any naturally occurring amino acid, and X at position 7 is proline or an analogue or derivative thereof. SEQ ID NO: 7: Synthetic peptide SEQ ID NO: 8: Synthetic peptide SEQ ID NO: 9: Synthetic peptide SEQ ID NO: 10: Synthetic peptide SEQ ID NO: 11: Synthetic peptide SEQ ID NO: 12: Synthetic peptide SEQ ID NO: 13: Synthetic peptide SEQ ID NO: 14: Synthetic peptide SEQ ID NO: 15: Synthetic peptide SEQ ID NO: 16: Synthetic peptide SEQ ID NO: 17: A synthetic peptide, in which X at position 1 is proline or an analogue or derivative thereof, X at position 2 is proline or an analogue thereof, X at position 3 is alanine, valine, leucine, cysteine, isoleucine, methionine, or any of their derivatives or analogues, X at position 4 is alanine, valine, serine, or any of their derivatives or analogues, Xaa at position 5 can be any naturally occurring amino acid, and X at position 6 is proline or an analogue or derivative thereof. SEQ ID NO: 18: Synthetic peptide SEQ ID NO: 19: synthetic peptide, amidated at position 5 SEQ ID NO: 20: synthetic peptide, position 1 may be a D amino acid and position 3 may be a D amino acid SEQ ID NO: 21: synthetic peptide, position 1 may be a D amino acid, position 3 may be a D amino acid, and position 5 may be a D amino acid

Claims

1. An isolated peptide consisting of the amino acid sequence shown in SEQ ID NO:3, SEQ ID NO:7 or SEQ ID NO:

20.

2. 2. The isolated peptide of claim 1 for use in treating an apoptosis-related disease.

3. The isolated peptide of claim 2 for use in treating an apoptosis-related disease, wherein the apoptosis-related disease is an inflammatory or degenerative disease.

4. A pharmaceutical composition comprising the peptide described in claim 1 as an active ingredient and further comprising a physiologically acceptable carrier.

Images